Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Klotho protein is an **anti-aging protein** that exists in two major forms: a **membrane-bound form** (130kDa transmembrane protein) and a **soluble form** (s-Klotho). The protein is primarily expressed in the **kidney**, with additional expression in the **brain** and **pancreas**. The membrane-bound form acts as a co-receptor for **fibroblast growth factor 23 (FGF23)** signaling and plays a crucial role in regulating **vitamin D metabolism** and **phosphate balance**. Both forms exhibit multiple pharmacological functions including **anti-inflammatory**, **anti-oxidative**, **anti-fibrotic**, and **tumor-suppressive** properties. Klotho functions through several mechanisms: it **blocks NF-κB signaling** and prevents its nuclear translocation, **suppresses TGF-β1/SMAD signaling**, **inhibits toll-like receptors (TLR2/4)**, and **reduces pro-inflammatory cytokines** (IL-6, IL-8, TNF-α). The protein also demonstrates **neuroprotective effects**, with studies showing enhanced **cognition and memory** in aged subjects. Klotho deficiency is associated with accelerated aging and various pathological conditions. As a therapeutic agent, recombinant Klotho protein has shown promising results in preclinical models for multiple conditions including **diabetic kidney disease (DKD)**, **cardiovascular diseases**, **Alzheimer's disease**, and **cancer**. The protein has a relatively **short half-life of approximately 7 hours** and is noted to be **unstable with sensitivity to freeze-thaw cycles**, which presents challenges for therapeutic development. Multiple academic institutions and biotechnology companies are investigating klotho protein therapeutically, though widespread clinical application remains in the exploratory phase. Various delivery methods are being explored including **recombinant protein administration**, **viral gene delivery**, and strategies to **upregulate endogenous production** through existing drugs like paricalcitol and sevelamer carbonate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on klotho protein.